• 1
    Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer. 1982; 45: 361366.
  • 2
    Duffy SW, Tabàr L, Fagerberg G, et al. Breast screening, prognostic factors and survival—results from the Swedish two county study. Br J Cancer. 1991; 64: 11331138.
  • 3
    Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 539 have been followed up for 15 years. Br J Cancer. 1957; 11: 359377.
  • 4
    Todd JH, Dowle C, Williams MR, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987; 56: 489492.
  • 5
    Lonn U, Lonn S, Nilsson B, Stenkvist B. Breast cancer: prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features. Breast Cancer Res Treat. 1994; 29: 237245.
  • 6
    Hensel M, Schneeweiss A, Sinn HP, et al. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer. 2002; 100: 290296.
  • 7
    Malmstrom P, Bendahl PO, Boiesen N, et al. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histological grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol. 2000; 19: 20102019.
  • 8
    Tabàr L, Chen HH, Duffy SW, et al. A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. Lancet 2000; 355: 429433.
  • 9
    Tabàr L, Duffy SW, Vitak B, Chen HH, Prevost TC. The natural history of breast carcinoma: what have we learned from screening? Cancer 1999; 86: 449462.
  • 10
    Langlands AO, Pocock SJ, Kerr GR, Gore SM. Long-term survival of patients with breast cancer: a study of the curability of the disease. BMJ. 1979; 2: 12471251.
  • 11
    Collett K, Skjaerven R, Maehle BO. The prognostic contribution of estrogen and progesterone receptor status to a modified version of the Nottingham Prognostic Index. Breast Cancer Res Treat. 1988; 48: 19.
  • 12
    Tabàr L, Fagerberg G, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985; 1: 829832.
  • 13
    Tabàr L, Fagerberg G, Duffy SW, Day NE, Gad A, Gröntoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am. 1992; 30: 187210.
  • 14
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187220.
  • 15
    Jenkins SP. Discrete time proportional hazards regression. Stata Technical Bulletin. Volume 39. College Station, TX: Stata Corporation, 1997: 2232.
  • 16
    Zahl PH, Tretli S. Long-term survival of breast cancer in Norway by age and clinical stage. Stat Med. 1997; 16(13): 14351449.
  • 17
    Tabàr L, Vitak B, Chen HH, et al. The Swedish Two-County Trial twenty years later: updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000; 38: 625651.